Drug intelligence / Profile preview

NAIN01

Development stage: Preclinical
Lead developer: Hangzhou Nain Biotechnology
Modality: Small Molecules

Overview

NAIN01 is a preclinical small molecule drug candidate developed by Hangzhou Nain Biotech. It is designed to target fatty acid amide hydrolase 1 (FAAH1) for the treatment of solid tumors. The drug is part of a pipeline developed using a platform that focuses on regulated cell death (RCD) and cancer stem cells (CSC) to overcome drug resistance in oncology. As a FAAH1 inhibitor, NAIN01 likely aims to modulate endocannabinoid levels within the tumor microenvironment, potentially influencing tumor growth and survival pathways associated with the company's focus on cell death mechanisms.

Targets

FAAH

Beyond the preview

Go deeper on NAIN01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NAIN01.

Explore the full profile